Med Ed Report briefs: June 2014

The Blood Sugar Basics website
The Blood Sugar Basics website

The ACCME put the University of Louisville CME program on probation after discovering that a physician employed by a pharma company taught at a course in Phoenix, AZ. The move came less than two months after another med-ed committee put the school on probation, The Courier-Journal reported.

Merck launched Blood Sugar Basics to improve physician-patient dialogue around proper A1C management. The program, aimed at PCPs who have patients with type 2 diabetes, debuted at May's American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress.

Despite advances in gout treatment, physician education remains the greatest unmet need in the therapeutics market, said research and consulting firm GlobalData. Most physicians “still do not take gout seriously enough,” its report says.

BroadcastMed announced enhancements, such as closed-captioning and enhanced search, to its online structured learning application. The application, open to HCPs on its network, supports learning activities sponsored by academic medical centers, medical device manufacturers and med-ed companies, the firm said.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.